Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system.
Walking Fish Therapeutics has raised $23.0M in total funding. The most recent round was Series A. The last funding was announced in February 2022.
Walking Fish Therapeutics's investors include First Spark Ventures, Quan Capital, Illumina Ventures, Emerson Collective, Northpond Ventures.
Walking Fish Therapeutics is headquartered in San Francisco, United States.
Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system.
Walking Fish Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Walking Fish Therapeutics — Funding & Investors." VCBacked, February 16, 2022, https://www.vcbacked.co/company/walking-fish-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Walking Fish Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/walking-fish-therapeutics
{{cite web |title=Walking Fish Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/walking-fish-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated